Esp1 Inhibitors
Esp1 inhibitors often target kinases such as Plk1, Aurora B, and CDK1, which are directly involved in the post-translational modification of Esp1, specifically phosphorylation. For example, BI-2536 inhibits Plk1, crucial for Esp1 activation, thereby ensuring that Esp1 remains in its inactive form. Roscovitine, a CDK1 inhibitor, impacts Esp1 by blocking the cell cycle at the G2-M transition, a critical point at which Esp1 is normally activated. Other inhibitors such as Hesperadin target Aurora B kinase, Esp1 phosphorylation and keeping it from promoting anaphase initiation.
In contrast, compounds like Nocodazole and Paclitaxel exert their influence by modulating the microtubule dynamics, which indirectly affects Esp1's role. Nocodazole disrupts microtubules, inhibiting the formation of the mitotic spindle, an essential prerequisite for Esp1 activation. Paclitaxel stabilizes microtubules, thus inhibiting the dynamics required for the activation of Esp1. Kinesin inhibitors such as Monastrol and STLC obstruct centrosome separation or spindle formation, leading to mitotic arrest and Esp1 activation. Collectively, these inhibitors modulate Esp1 through diverse biochemical mechanisms.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
CDK1 inhibitor, blocking progression from G2 to M phase. Esp1, essential in anaphase initiation, is impacted as its activation depends on the cell cycle reaching the M phase. | ||||||
BI 2536 | 755038-02-9 | sc-364431 sc-364431A | 5 mg 50 mg | $151.00 $525.00 | 8 | |
Inhibits Plk1, which is responsible for Esp1 phosphorylation. Without this post-translational modification, Esp1 remains in its inactive form. | ||||||
Hesperadin | 422513-13-1 | sc-490384 | 10 mg | $304.00 | ||
Inhibits Aurora B kinase, which affects the phosphorylation of Esp1, thereby keeping it from participating in chromosome separation during anaphase. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Microtubule-disrupting agent that prevents the formation of the mitotic spindle, an event that precedes Esp1 activation for anaphase initiation. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
Glycogen synthase kinase-3 (GSK-3) inhibitor affecting the Esp1 localization by disrupting the balance of spindle-associated proteins. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Stabilizes microtubules, thereby inhibiting their dynamics which is crucial for Esp1 activation during the metaphase-anaphase transition. | ||||||
Monastrol | 254753-54-3 | sc-202710 sc-202710A | 1 mg 5 mg | $120.00 $233.00 | 10 | |
Kinesin Eg5 inhibitor which blocks centrosome separation, leading to mitotic arrest. This indirectly prevents Esp1 from facilitating anaphase initiation. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
Aurora kinase inhibitor that hampers the kinase activity needed for Esp1 phosphorylation and subsequent activation. | ||||||
MLN 8054 | 869363-13-3 | sc-484828 | 5 mg | $398.00 | ||
Aurora A kinase inhibitor that prevents Esp1 from phosphorylation, necessary for its activation and function in chromosome separation. | ||||||
S-Trityl-L-cysteine | 2799-07-7 | sc-202799 sc-202799A | 1 g 5 g | $32.00 $66.00 | 6 | |
Kinesin Eg5 inhibitor leading to monoastral spindle formation, subsequently impeding the process that would otherwise lead to Esp1 activation. | ||||||